Medtronic Stock Price, News & Analysis

Medtronic plc (NYSE:MDT) has received FDA clearance for the LINQ II Insertable Cardiac Monitor (ICM), marking it the first and only device cleared for long-term monitoring in pediatric patients over the age of 2 with heart rhythm abnormalities. This innovation is significant for pediatric cardiologists, offering critical data for diagnosing and managing heart conditions.

The LINQ II ICM is compact, wireless, and features a battery life of up to 4.5 years. It incorporates AccuRhythm AI algorithms, reducing false alerts significantly while ensuring accurate monitoring.

Medtronic announced long-term results from the SYMPLICITY HTN-3 clinical trial at the TCT conference, showing significant reductions in blood pressure for patients undergoing renal denervation. Over three years, RDN patients experienced a 26.4 mm Hg reduction in office systolic blood pressure, compared to 5.7 mm Hg for the sham control group. The trial included 535 patients, with no long-term complications reported. These findings contribute to the growing evidence supporting the safety and efficacy of the Symplicity blood pressure procedure, which is approved for use in over 60 countries, though still investigational in the U.S.

Medtronic plc (NYSE:MDT) announced the pricing of €4.5 billion in senior notes by its subsidiary, Medtronic Luxco. This includes €500 million of 2.625% notes due 2025, €1 billion of 3.000% notes due 2028, €1 billion of 3.125% notes due 2031, and €1 billion of 3.375% notes due 2034. The proceeds will be used to repay existing notes and for general corporate purposes. The offering is set to close on September 21, 2022, pending customary conditions, with Barclays, BofA, Citigroup, and HSBC acting as joint book-running managers.

Ra Medical Systems (RMED) has announced a merger with Catheter Precision, a medical device company focusing on cardiac electrophysiology. This stock-for-stock reverse merger will result in Catheter Precision becoming a wholly owned subsidiary of Ra Medical. Catheter Precision's lead product, VIVO™, aims to improve treatment for ventricular arrhythmias, a significant market opportunity. The merger is expected to close by the end of 2022, pending shareholder approval. Post-merger, Catheter Precision stakeholders are projected to own 80% of the combined entity, enhancing growth potential in the cardiac market.

Medtronic plc (NYSE:MDT) announced its participation in several September 2022 investor conferences, enhancing its commitment to engage with investors and stakeholders. Key events include the Wells Fargo 2022 Healthcare Conference on September 7, featuring CFO Karen Parkhill; the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 with CEO Geoff Martha; and the Bank of America Global Healthcare Conference on September 15, led by Rob ten Hoedt. Live webcasts of these sessions will be accessible on the company’s investor relations website.

Medtronic (NYSE:MDT) announced successful results from the ADAPT study, published in The Lancet Diabetes & Endocrinology. The study highlighted a 1.4% reduction in HbA1c and a 27.6% increase in Time in Range for users of the MiniMed 780G system compared to standard care (MDI + isCGM). Of participants using the MiniMed system, 27.8% achieved HbA1c below 7%, while none achieved this with standard care. The study indicates significant improvements in glucose control and patient satisfaction, reinforcing the adoption of insulin pump therapy for better diabetes management.

Medtronic plc (NYSE:MDT) has announced a strategic partnership with BioIntelliSense for exclusive U.S. distribution rights of the BioButton® wearable device. This partnership aims to enhance patient monitoring by providing up to 1,440 daily vital sign measurements, facilitating continuous remote monitoring from hospital to home. The collaboration addresses staffing shortages in healthcare and supports workflow automation for clinicians. With the BioButton integrated into Medtronic's HealthCast™ portfolio, the goal is to improve patient safety and enable proactive clinical interventions.

Medtronic plc (NYSE:MDT) has finalized its acquisition of Affera, Inc., enhancing its cardiac ablation portfolio with a new cardiac mapping and navigation platform. This acquisition introduces the Affera Prism-1™ system, compatible with various therapeutic catheters, aimed at treating cardiac arrhythmias, particularly atrial fibrillation (AF). The acquisition is expected to be less than 1% dilutive to adjusted earnings per share in the first three years, with anticipated impacts of 3 to 4 cents in fiscal year 2023, 5 cents in fiscal year 2024, and 4 cents in fiscal year 2025.

Medtronic (NYSE: MDT) announced positive results from its global clinical trial for the investigational EV ICD™ System, achieving a defibrillation success rate of 98.7% and exceeding safety endpoints. The study, revealed at ESC Congress 2022, showed that the device's effectiveness surpassed the prespecified performance goal of 88%. The EV ICD is designed to treat fast heart rhythms while minimizing risks linked to traditional ICDs. With 92.6% of patients free from major complications at six months, the findings suggest significant potential for this innovative technology in cardiac care.